NKGN vs. CRTX, PLUR, SRZN, INKT, TARA, BCLI, ACHL, AIM, ZIVO, and EVAX
Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Cortexyme (CRTX), Pluri (PLUR), Surrozen (SRZN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), Brainstorm Cell Therapeutics (BCLI), Achilles Therapeutics (ACHL), AIM ImmunoTech (AIM), ZIVO Bioscience (ZIVO), and Evaxion Biotech A/S (EVAX). These companies are all part of the "medical" sector.
NKGen Biotech (NYSE:NKGN) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.
NKGen Biotech has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.
76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by company insiders. Comparatively, 27.9% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
NKGen Biotech's return on equity of 0.00% beat Cortexyme's return on equity.
Cortexyme received 154 more outperform votes than NKGen Biotech when rated by MarketBeat users.
NKGen Biotech has higher revenue and earnings than Cortexyme.
In the previous week, NKGen Biotech had 1 more articles in the media than Cortexyme. MarketBeat recorded 1 mentions for NKGen Biotech and 0 mentions for Cortexyme. NKGen Biotech's average media sentiment score of 0.00 equaled Cortexyme'saverage media sentiment score.
Summary
NKGen Biotech beats Cortexyme on 5 of the 9 factors compared between the two stocks.
Get NKGen Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NKGen Biotech Competitors List
Related Companies and Tools
